Insider Selling: SOPHiA GENETICS (NASDAQ:SOPH) Insider Sells $38,147.88 in Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) insider Philippe Menu sold 7,393 shares of the company’s stock in a transaction dated Monday, July 6th. The shares were sold at an average price of $5.16, for a total transaction of $38,147.88. Following the sale, the insider owned 233,387 shares in the company, valued at $1,204,276.92. This represents a 3.07% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Philippe Menu also recently made the following trade(s):

• On Thursday, June 25th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.50, for a total value of $27,500.00.
• On Tuesday, May 26th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.95, for a total value of $24,750.00.
• On Monday, April 27th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.82, for a total value of $24,100.00.
• On Monday, April 20th, Philippe Menu sold 608 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.20, for a total value of $3,161.60.
• On Tuesday, April 14th, Philippe Menu sold 1,600 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.96, for a total value of $7,936.00.
• On Monday, April 13th, Philippe Menu sold 4,400 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.76, for a total value of $20,944.00.
• On Friday, April 10th, Philippe Menu sold 3,725 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.68, for a total value of $17,433.00.
• On Thursday, April 9th, Philippe Menu sold 1,931 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.74, for a total value of $9,152.94.
• On Wednesday, April 8th, Philippe Menu sold 2,800 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.84, for a total transaction of $13,552.00.

SOPHiA GENETICS Trading Up 1.9%

SOPH stock traded up $0.10 during mid-day trading on Tuesday, reaching $5.44. 284,563 shares of the stock traded hands, compared to its average volume of 187,273. SOPHiA GENETICS SA has a one year low of $2.92 and a one year high of $6.30. The stock has a market capitalization of $456.36 million, a PE ratio of -10.46 and a beta of 0.96. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.90 and a current ratio of 2.06. The business has a 50-day moving average price of $5.12 and a two-hundred day moving average price of $4.96.

SOPHiA GENETICS (NASDAQ:SOPH) last released its earnings results on Tuesday, May 5th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.04). SOPHiA GENETICS had a negative return on equity of 62.74% and a negative net margin of 44.48%.The firm had revenue of $21.69 million during the quarter, compared to the consensus estimate of $20.40 million.

Analyst Ratings Changes

Several research analysts have issued reports on SOPH shares. Weiss Ratings restated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Tuesday, April 21st. BTIG Research restated a “buy” rating and set a $8.00 price objective on shares of SOPHiA GENETICS in a report on Monday, June 15th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, SOPHiA GENETICS has a consensus rating of “Hold” and a consensus price target of $7.50.

Hedge Funds Weigh In On SOPHiA GENETICS

Hedge funds have recently added to or reduced their stakes in the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of SOPHiA GENETICS by 246.9% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company’s stock valued at $25,341,000 after acquiring an additional 5,432,871 shares in the last quarter. Akre Capital Management LLC grew its stake in SOPHiA GENETICS by 66.2% in the second quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company’s stock worth $11,529,000 after purchasing an additional 1,481,636 shares in the last quarter. Hodges Capital Management Inc. bought a new position in SOPHiA GENETICS in the first quarter worth approximately $2,157,000. Royce & Associates LP purchased a new position in SOPHiA GENETICS during the 4th quarter worth $2,009,000. Finally, Sei Investments Co. purchased a new position in SOPHiA GENETICS during the 1st quarter worth $1,772,000. 31.59% of the stock is currently owned by institutional investors.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.